GIC, the Singapore investment firm managing the state’s foreign reserves, has led a US$260 million (RMB1.653 billion) series B financing in CStone, a Chinese bio-pharmaceutical company. GIC was joined by existing investors Oriza Seed Venture Capital, Boyu Capital, and 6 Dimensions Capital, formerly WuXi Healthcare Ventures. New investors Sequoia Capital China, Yunfeng Capital, Taikang Insurance Group, CITIC PE, ARCH Venture Partners, Hillhouse Capital and King Star Capital also participated in the round. Founded in 2016 with headquarters in Suzhou, China, …

Singapore’s GIC Leads $260M Series B Round In Chinese Biopharma Company CStone appeared first on China Money Network.


Visit the original source and full text: China Money Network